Pancreatic Cysts in Northern Virginia: Types and Monitoring

← Patient Education

Pancreatic cysts are one of the more common incidental findings in Northern Virginia and everywhere else abdominal imaging is done, and one of the more alarming to read about in a radiology report. The typical story is a CT or MRI ordered for something unrelated, a kidney stone, back pain, a gallbladder question, and a line near the bottom of the report noting a small cystic lesion in the pancreas with a recommendation for follow-up. Most people who read that line have never heard of pancreatic cysts, and the first search result they find is about pancreatic cancer. The accurate picture is considerably calmer. The American College of Gastroenterology, in its 2018 clinical guideline on pancreatic cysts, states that pancreatic cysts are very common, that the majority are found by accident, and that even the types with malignant potential rarely progress to cancer. This guide explains what pancreatic cysts are, the main types, how gastroenterologists tell them apart, what the surveillance plan looks like, and which specific features would change that plan.

This is an area where the physician's training matters. Characterizing a pancreatic cyst often requires endoscopic ultrasound, a specialized procedure, and interpreting the result requires familiarity with guidelines that have changed several times in the past decade. Our practice includes a gastroenterologist with advanced endoscopy fellowship training in exactly this area. This article is general education, not medical advice.

What pancreatic cysts are

The pancreas is a gland that sits behind the stomach and produces digestive enzymes and the hormones that regulate blood sugar, including insulin. A pancreatic cyst is a fluid-filled sac in or on the pancreas. Some are simple pockets of fluid left behind by inflammation. Others are growths whose cells produce fluid, and it is that second group, called cystic neoplasms, that requires sorting, because a few of them can slowly change over years toward cancer while most never do.

The word "neoplasm" alarms people, and it is worth defining. A neoplasm is an abnormal growth of cells. It is not a synonym for cancer. Most cystic neoplasms of the pancreas are benign at the time they are found, and the entire purpose of evaluation and surveillance is to identify the small minority that are changing while leaving the rest alone.

How common pancreatic cysts are, and why they are found more often now

Pancreatic cysts are far more common than most people realize, and they become more common with age. The ACG guideline cites a prevalence in asymptomatic people of 2.4 to 13.5 percent, rising with age, and notes that a review of abdominal MRIs done for non-pancreatic reasons in people over 70 found incidental pancreatic cysts in 40 percent. A 2024 systematic review and meta-analysis of 15 studies and 65,607 people, available through the National Institutes of Health's PubMed Central, pooled the prevalence of pancreatic cystic lesions on MRI in the general population at 16 percent, most of them under 10 millimeters. The age pattern was striking: 9 percent at ages 50 to 59, 18 percent at 60 to 69, 26 percent at 70 to 79, and 38 percent at 80 and older. Men and women were affected at the same rate.

Two things follow from those numbers. First, a pancreatic cyst in an adult over 60 is closer to an ordinary finding than a rare one. Second, the reason cysts seem to be everywhere now is not that the pancreas has changed. The ACG guideline points out that pancreatic cancer mortality has been fairly stable, so the rising number of cysts reflects more imaging, and better imaging, rather than more disease. The same guideline offers a reassuring detail about size: across 25,195 people in five studies, cysts larger than 2 centimeters were found in only 0.8 percent. The great majority of incidental pancreatic cysts are small.

Types of pancreatic cysts

The ACG guideline divides pancreatic cysts into non-neoplastic and neoplastic types, and within the neoplastic group, into those that produce mucin and those that do not. Mucin is the thick, gel-like secretion that distinguishes the types with malignant potential. The main types, drawn from the guideline's summary table, are:

• Pseudocyst. A non-neoplastic collection of fluid, and sometimes debris, that forms after acute or chronic pancreatitis when damaged ducts leak enzyme-rich fluid. The National Library of Medicine's MedlinePlus encyclopedia describes pseudocysts as arising most often after an episode of severe acute pancreatitis, and notes that many resolve on their own. Pseudocysts have no malignant potential. The clue is usually the history: a pseudocyst in someone who has never had pancreatitis or abdominal trauma is unlikely to be a pseudocyst at all. Our guide to pancreatitis in Northern Virginia covers the underlying condition.
• Serous cystadenoma. A benign neoplasm, found in women three times out of four, most often in the 60s. It typically has a honeycomb or microcystic appearance on imaging. The ACG states that serous cystadenomas have a very low risk of malignant transformation and, when confidently diagnosed, do not require treatment or further evaluation.
• Intraductal papillary mucinous neoplasm (IPMN). A mucin-producing growth that arises within the pancreatic ducts, affecting men and women equally, most often in the 70s. IPMNs are classified by which duct they involve. A side-branch (also called branch-duct) IPMN grows in a small tributary duct, is the most common incidental pancreatic cyst, carries a low risk of cancer progression, and is often multiple. A main-duct IPMN involves the central pancreatic duct, is much less common, and carries a higher risk. Mixed IPMNs involve both and are treated like main-duct disease. The ACG guideline states plainly that the majority of incidentally found pancreatic cysts are side-branch IPMNs.
• Mucinous cystic neoplasm (MCN). A mucin-producing cyst found almost exclusively in women, typically between the 40s and 60s, and usually in the body or tail of the pancreas. Unlike an IPMN, it does not connect to the pancreatic duct. MCNs have malignant potential and are managed on the same surveillance framework as IPMNs.
• Solid-pseudopapillary neoplasm. An uncommon tumor with both solid and cystic parts, found in women ten times more often than men and most often in the 20s. The ACG recommends referral to a multidisciplinary group for consideration of surgical removal.
• Cystic neuroendocrine tumor. A neuroendocrine tumor that has developed a cystic component. Usually non-functioning, meaning it does not produce excess hormones, and identified by the cell type seen on a sample.

The practical distinction a gastroenterologist is trying to make is between the mucin-producing cysts, IPMNs and MCNs, which are watched, and everything else, which for the most part is either left alone (pseudocysts, serous cystadenomas) or referred for surgical discussion (solid-pseudopapillary neoplasms).

Do pancreatic cysts cause symptoms

Usually not. The first recommendation in the ACG guideline is caution when attributing symptoms to a pancreatic cyst, because the majority are asymptomatic and the symptoms sometimes blamed on them, vague abdominal discomfort, bloating, back pain, are nonspecific and far more often have another cause. That matters in both directions. A cyst found during a workup for abdominal pain is not necessarily the explanation for the pain, and the pain workup should continue. And the absence of symptoms says nothing about whether a cyst needs follow-up, because the cysts that do warrant surveillance are almost always silent too.

The exceptions are specific and are treated as warning signs rather than ordinary symptoms. Jaundice, a yellowing of the skin and eyes caused by a cyst in the head of the pancreas pressing on the bile duct, and an episode of acute pancreatitis caused by the cyst, are both listed by the ACG among the high-risk features that call for further evaluation. Pseudocysts are the type most likely to cause symptoms in their own right. MedlinePlus lists bloating, persistent deep abdominal or back pain, nausea, vomiting, and difficulty eating, and warns that a pseudocyst that ruptures is a medical emergency.

How pancreatic cysts are evaluated

The evaluation has two goals: figure out what type of cyst it is, and look for any feature suggesting it is more than a low-risk cyst. The tools are imaging, sometimes a closer look with endoscopic ultrasound, and sometimes a sample of the fluid inside.

MRI is the preferred test. The ACG recommends MRI, or MRCP, a version of MRI that focuses on the pancreatic and bile ducts, as the test of choice, because it involves no radiation and is the most accurate way to see whether a cyst communicates with the main pancreatic duct, which is the signature of a side-branch IPMN. A pancreatic-protocol CT scan is a good alternative for people who cannot have an MRI. The guideline also adds a caution that is worth knowing before a follow-up visit: the accuracy of MRI in identifying the cyst type is only 40 to 50 percent, and in distinguishing benign from malignant, 55 to 76 percent. Imaging narrows the possibilities. It often does not settle them.

Endoscopic ultrasound gives the closest view. When the type is unclear, or when the cyst has features that need a closer look, the next step is usually an endoscopic ultrasound in Northern Virginia, or EUS. A thin scope with an ultrasound probe at its tip is passed through the mouth into the stomach and the first part of the small intestine, which sit directly against the pancreas. From there the probe images the cyst from a few millimeters away, showing its wall, any internal septations or nodules, and its relationship to the duct in far more detail than a scan taken through the abdominal wall. The ACG guideline names EUS as an excellent alternative to MRI when MRI is not possible and as a primary surveillance tool for people who cannot or choose not to have MRI scans.

Cyst fluid analysis, when it would change the plan. During an EUS, a fine needle can be passed into the cyst to draw fluid for analysis. The ACG recommends considering this when the diagnosis is unclear and the results are likely to alter management. Three things are commonly measured. A protein called CEA tends to be high in mucin-producing cysts and low in serous cystadenomas and pseudocysts, so it helps distinguish the types that need watching from the types that do not, although the guideline is explicit that CEA cannot tell whether an IPMN or MCN already contains high-grade changes. Amylase, a pancreatic enzyme, tends to be high in pseudocysts and IPMNs, which communicate with the duct, and low in cysts that do not. Cytology, an examination of the cells in the fluid, is sent to look for high-grade dysplasia or cancer when imaging alone is not enough to make a decision. Molecular marker testing of the fluid is an additional option in unclear cases. The EUS page above describes the procedure, the sedation, and the small risks of sampling in detail.

What the risk of cancer actually is

This is the question behind every follow-up appointment, and the guideline answers it with unusual candor. The ACG states that when all individuals with pancreatic cysts are considered together, the potential risk of malignant transformation is small. It cites an analysis of the national SEER cancer database estimating that the probability a cyst harbors cancer at the time it is imaged is 0.25 percent, with an overall conversion rate to invasive cancer of 0.24 percent per year. The guideline also reports that surgical series show much higher rates, because the cysts that reach surgery are the ones that already looked concerning, and it notes that estimates vary widely between studies.

For IPMNs specifically, the guideline reports one review of 3,980 people with suspected IPMNs that found an overall risk of developing pancreatic cancer of 2.8 percent, and a separate analysis that split IPMNs by risk: for low-risk IPMNs, those without a nodule or a dilated main duct, the pooled cumulative risk of high-grade dysplasia or cancer was 0.02 percent at one year, 3.12 percent at five years, and 7.77 percent at ten years. For high-risk IPMNs the figures were 1.95, 9.77, and 24.68 percent. The 2024 Kyoto international guidelines on IPMN, published by the International Association of Pancreatology, estimate that the transformation of an indolent branch-duct IPMN to high-grade dysplasia or invasive cancer accumulates at roughly 0.94 to 3.3 percent by five years, 2.3 to 6.6 percent by ten years, and 7.6 to 15 percent at fifteen years, and that it occurs more often in cysts that were larger, or had a wider main duct, at the time of diagnosis.

Two honest conclusions come from this. The risk for a typical small side-branch IPMN is low, and low is not zero. The Kyoto guidelines also note that the risk does not fall away with time; it accumulates. That is the reason the plan for most cysts is surveillance rather than either surgery or dismissal.

The features that change the plan

Surveillance is the default. What moves a cyst out of the default is a short list of findings, on imaging, on blood work, or in the patient's history, that guidelines associate with a higher likelihood of high-grade change. The ACG guideline's list of high-risk characteristics for mucinous pancreatic cysts, which is the list our physicians work from, includes:

• Jaundice caused by the cyst
• Acute pancreatitis caused by the cyst
• An elevated blood level of the tumor marker CA 19-9 when no benign explanation is present
• A mural nodule or solid component, meaning a bump of tissue growing from the cyst wall or a solid mass in the surrounding pancreas
• A main pancreatic duct wider than 5 millimeters
• A change in the caliber of the main duct with shrinkage of the pancreas beyond it
• A cyst larger than 3 centimeters
• Growth of more than 3 millimeters per year
• High-grade dysplasia or cancer on cytology

The ACG makes a strong recommendation that a person with an IPMN or MCN and any of these features undergo EUS, with fluid sampling where appropriate, and be referred to a multidisciplinary group for further evaluation. It separately flags new-onset or worsening diabetes as a reason for a short-interval MRI or EUS, because a growth in the pancreas can impair insulin production.

The 2024 Kyoto guidelines organize a similar list into two tiers, which is how many radiology reports now phrase their findings. High-risk stigmata are the strongest predictors: obstructive jaundice from a cyst in the head of the pancreas, an enhancing mural nodule of 5 millimeters or more or a solid component, a main pancreatic duct of 10 millimeters or more, and suspicious or positive cytology. Worrisome features are the softer signals: acute pancreatitis, an elevated CA 19-9, new-onset or recently worsened diabetes within the past year, a cyst of 30 millimeters or more, an enhancing nodule under 5 millimeters, a thickened or enhancing cyst wall, a main duct of 5 to under 10 millimeters, an abrupt change in duct caliber with atrophy beyond it, enlarged lymph nodes, and a growth rate of 2.5 millimeters or more per year. A single worrisome feature generally prompts a closer look with EUS rather than surgery. High-risk stigmata generally prompt a surgical conversation.

If your report uses these terms, the presence of one does not mean cancer. It means the cyst has left the lowest-risk category and the next step is a more detailed look, which is precisely what a gastroenterologist with EUS training is for. If none of these terms appear in your report, that is the more common outcome, and it is good news.

Pancreatic cyst surveillance: what monitoring looks like

For a presumed IPMN or MCN with no concerning features, the plan is periodic imaging, and the interval is set mainly by the size of the cyst, because larger cysts progress more often and sooner. The ACG guideline states that in the absence of concerning features, cyst size guides the surveillance interval, and that MRCP is the preferred surveillance test because it involves no radiation and shows the main duct well. The 2024 Kyoto guidelines, which are the most recent international consensus, give a specific size-based schedule for branch-duct IPMNs. After an initial short-term follow-up scan at six months to establish that the cyst is stable, the recommended intervals are:

• Under 20 millimeters: every 18 months
• 20 to under 30 millimeters: every 12 months, after two six-month checks
• 30 millimeters or more: every 6 months

The Kyoto guidelines support this with progression data: among branch-duct IPMNs under 10 millimeters, about 4.8 percent developed a worrisome feature over a median of 54 months; between 10 and 20 millimeters, 10 percent at 55 months; and between 20 and 30 millimeters, 48.8 percent at a median of 23 months. Bigger cysts earn closer watching because they change more. Individual practices and radiology groups sometimes follow slightly different schedules, including the ACG's own size-based algorithm, and the exact plan for any one person is set by the physician following the cyst. What does not vary is the principle: small, stable, featureless cysts are checked infrequently, and a change in size, in the duct, or in the cyst wall shortens the interval and usually adds an EUS.

A few practical points about living with surveillance. The scans are outpatient MRIs with no preparation beyond what any MRI requires. Between scans, the two things worth reporting to your physician promptly are a new diagnosis of diabetes, or an unexplained worsening of existing diabetes, and any episode of abdominal pain severe enough to suggest pancreatitis, since both are on the list above. Neither is common, and both are reasons to move the next scan up rather than reasons for alarm. If you change physicians or move, take the prior reports with you. Surveillance depends on comparison with earlier images, and a cyst with no baseline is harder to interpret than a cyst with three years of stability behind it.

When surveillance can stop

This is one of the places where guidelines have shifted. Both the ACG and Kyoto guidelines agree that surveillance should stop when a person is no longer a candidate for surgery, because the only treatment for a cyst that turns is surgical removal, and monitoring for something that would not be acted on serves no purpose. The ACG says that it is reasonable to reassess the value of ongoing surveillance after age 75, with an individualized discussion for those between 76 and 85.

The Kyoto guidelines go a step further for the smallest cysts. They state that surveillance may be discontinued for a cyst under 20 millimeters that has shown no change in appearance and no worrisome features after five years, taking the person's condition and life expectancy into account. They add two important caveats: this does not apply to younger patients, because the risk accumulates over a lifetime, and it does not apply to people with a family history of pancreatic cancer or a known genetic risk. The guidelines are also candid that experts disagree, noting Japanese data in which cancers continued to appear in people with small stable cysts beyond five years, and they present "stop surveillance" and "continue surveillance" as two acceptable options to be decided between physician and patient. If you have been followed for years for a small unchanged cyst, that conversation is worth having.

When surgery is discussed

Surgery is reserved for cysts with high-risk features, and the reason is that pancreatic surgery is a major operation. The ACG guideline cites a literature review putting the mortality rate of pancreatic resection for cysts at 2.1 percent and the complication rate at 30 percent. Those figures are why guidelines set a high bar before recommending removal, why the ACG advises against evaluating cysts at all in people who could not undergo surgery, and why even a cyst with a worrisome feature is typically examined further before anyone recommends an operation. Removing a pancreatic cyst that would never have caused harm exposes a person to real risk for no benefit. The entire surveillance framework exists to make that mistake rare in both directions.

When surgery is warranted, it is performed by a pancreatic surgeon, usually within a multidisciplinary team that includes gastroenterology, radiology, and pathology. A gastroenterologist's role is the evaluation that leads there: characterizing the cyst, performing the EUS and fluid sampling, and making the referral when the findings justify it. After removal, follow-up depends on what the pathologist finds. The ACG states that a resected serous cystadenoma or pseudocyst needs no further follow-up, that a resected MCN without cancer needs no postoperative surveillance, and that all resected IPMNs require continued surveillance, because the rest of the pancreas remains at risk.

Pancreatic cysts in Northern Virginia: care with GC of NoVA

Gastroenterology Center of Northern Virginia evaluates and follows pancreatic cysts for patients across Arlington, Annandale, and the surrounding communities. Pancreatic and biliary conditions often call for advanced endoscopic procedures, and our practice includes Diego I. Kuperschmit, M.D., who completed an advanced endoscopic fellowship at Beth Israel Medical Center in New York City with training in endoscopic ultrasound and ERCP. That training supports the evaluation of a newly found pancreatic cyst, the interpretation of imaging against current guidelines, and the decision about whether EUS with fluid analysis would change the plan. Where a cyst warrants a surgical opinion, we coordinate the referral. We see patients at our Arlington office, next to VHC Health, and our Annandale office, in the Woodburn Medical complex. If this would be your first visit with a gastroenterologist, our guide to what to expect at a first appointment explains how the visit goes, and our guide to when to see a gastroenterologist covers the broader decision. If you bring one thing to that visit, bring the imaging report and, if possible, the images themselves.

To schedule an evaluation, contact our Arlington office at (703) 522-7476 or our Annandale office at (703) 560-6106, or learn more at gcofnova.com.

This article is for general education and is not medical advice. Talk with a qualified gastroenterologist about your symptoms, diagnosis, and treatment options.